BioSpace News Archive

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 7, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming mi

Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients

Nines Makes AI to Detect Emergent Conditions Available Free To Customers Including Those Overwhelmed By COVID-19 Diagnostics

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, announced the pricing of its underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share.

MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone® platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria).

The C-Suite At the Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully closed the acquisition of selected life science businesses of Danaher Corporation.

Sonic Healthcare USA’s COVID-19 Taskforce Medical and Scientific Advisors have developed a novel Return-to-Work protocol consisting of laboratory testing algorithms intended to help guide employers and worksite health practitioners with their strategies to return workers and optimize ongoing monitoring and prevention.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2020 financial results after the close of market on Thursday, May 7, 2020

VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, today announced that the initial clinical trial results of VIVEX’s VAST Trial evaluating VIA® Disc were published in the peer-reviewed journal The International Journal of Spine Surgery.